Alpha Synuclein Seeding Assays plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Alpha Synuclein Seeding Assays is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
Alpha-synuclein seeding assays are ultra-sensitive diagnostic tests that detect the presence of pathological alpha-synuclein aggregates in biological samples. These assays exploit the prion-like property of alpha-synuclein to convert normal protein into its pathological form, enabling detection of neurodegeneration at earlier stages than conventional biomarkers. [2]
The fundamental principle underlying seeding assays is that pathological alpha-synuclein (aSyn) possesses a conformations capable of "templating" or "seeding" the conversion of normal, monomeric aSyn into the misfolded, aggregated form. This property is similar to prion diseases and is thought to be fundamental to the spread of pathology in Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). [3]
Key aspects of seeding: [4]
RT-QuIC is the most widely validated seeding assay for aSyn. The assay uses recombinant aSyn substrate that is incubated with the patient sample under controlled shaking conditions. [5]
PMCA amplifies pathological seeds through repeated cycles of incubation and sonication, similar to techniques used for prion detection. [6]
Alpha-synuclein seeding assays have shown remarkable diagnostic utility in PD: [7]
Seeding assays may enable:
Preliminary data suggest potential for:
Alpha Synuclein Seeding Assays plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Kang UJ, Boehme M, Fairfoul G, et al. Comparative study of cerebrospinal fluid α-synuclein seeding assays in Parkinson's disease. Ann Neurol. 2023. ↩︎
Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating α-synucleinopathies in Parkinson's disease and multiple system atrophy. Nat Med. 2020. ↩︎
Concha-Marambio L, Chighladze M, Standaert DG, et al. Detection of pathological α-synuclein aggregates in CSF and blood by RT-QuIC and PMCA. Acta Neuropathol. 2023. ↩︎
Singer W, Schmeichel AM, Shahnawaz M, et al. Alpha-synuclein seed amplification assay in isolated dystymic synucleinopathies. Neurology. 2023. ↩︎
Poggiolini I, Guermani A, D'Este E, et al. RT-QuIC screening for α-synuclein aggregation in neurodegenerative diseases. Brain. 2024. ↩︎
Iranzo A, Fairfoul G, Ayudhaya ABM, et al. [Detection of α-synuclein in CSF by RT-QuIC in isolated REM sleep behavior disorder](https://doi.org/10.1016/S1474-4422(22). Lancet Neurol. 2022. ↩︎
Van Buren D, Bhattacharya S, Weintraub D, et al. Clinical utility of α-synuclein seed amplification assay in diagnosing parkinsonism. Neurology. 2024. ↩︎